Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Arechederra

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Clinical Science (London, England : 1979)|September 20, 2024
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)Amaya Lopez-Pascual, Joan S Russo-Cabrera, Nuria Ardaiz, et al.
Gut|April 25, 2020
Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosisMarina Barcena-Varela, Hannah Paish, Laura Alvarez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 13, 2026
Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in HepatoblastomaLuz A Martínez-Pérez, M Ujue Latasa, Iker Uriarte, et al.
Journal of Hepatology|June 11, 2023
Identification and experimental validation of druggable epigenetic targets in hepatoblastomaAlex Clavería-Cabello, Jose Maria Herranz, Maria Ujue Latasa, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 14, 2025
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinomaDaniel Oyon, Amaya Lopez-Pascual, Borja Castello-Uribe, et al.
Gut|July 21, 2021
Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary stricturesMaria Arechederra, María Rullán, Irene Amat, et al.
Cell Reports. Medicine|April 2, 2026
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinomaElena Adan-Villaescusa, Borja Castello-Uribe, Iker Uriarte, et al.
Gut|September 12, 2024
Identification of PRMT5 as a therapeutic target in cholangiocarcinomaJasmin Elurbide, Leticia Colyn, Maria U Latasa, et al.
Hepatology (Baltimore, Md.)|November 22, 2020
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental CholangiocarcinomaLeticia Colyn, Marina Bárcena-Varela, Gloria Álvarez-Sola, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 26, 2022
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogrammingLeticia Colyn, Gloria Alvarez-Sola, M Ujue Latasa, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Science (London, England : 1979)|September 20, 2024
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)Amaya Lopez-Pascual, Joan S Russo-Cabrera, Nuria Ardaiz, et al.
Gut|April 25, 2020
Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosisMarina Barcena-Varela, Hannah Paish, Laura Alvarez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 13, 2026
Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in HepatoblastomaLuz A Martínez-Pérez, M Ujue Latasa, Iker Uriarte, et al.
Journal of Hepatology|June 11, 2023
Identification and experimental validation of druggable epigenetic targets in hepatoblastomaAlex Clavería-Cabello, Jose Maria Herranz, Maria Ujue Latasa, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 14, 2025
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinomaDaniel Oyon, Amaya Lopez-Pascual, Borja Castello-Uribe, et al.
Gut|July 21, 2021
Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary stricturesMaria Arechederra, María Rullán, Irene Amat, et al.
Cell Reports. Medicine|April 2, 2026
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinomaElena Adan-Villaescusa, Borja Castello-Uribe, Iker Uriarte, et al.
Gut|September 12, 2024
Identification of PRMT5 as a therapeutic target in cholangiocarcinomaJasmin Elurbide, Leticia Colyn, Maria U Latasa, et al.
Hepatology (Baltimore, Md.)|November 22, 2020
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental CholangiocarcinomaLeticia Colyn, Marina Bárcena-Varela, Gloria Álvarez-Sola, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 26, 2022
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogrammingLeticia Colyn, Gloria Alvarez-Sola, M Ujue Latasa, et al.
Pageof 4